Clinical Trial News
Insilico Medicine Reports Positive Phase IIa Results for ISM001-055, a Novel First-in-Class ...
ISM001-055, an AI-designed drug targeting TNIK for IPF, showed favorable safety and dose-dependent lung function improvement in a Phase IIa trial.
Tap into the A4 Study for unprecedented Alzheimer's clinical trial data
NIA releases A4 Study data and biosamples for Alzheimer’s research, despite trial drug not meeting primary endpoints. The data, from nearly 1,200 participants, has generated over 60 peer-reviewed articles and insights on disease biology and biomarkers. Available at www.a4studydata.org, with further discussions at the 2024 NIH Alzheimer’s Research Summit.
Praxis Precision's relutrigine reduces seizures in rare epileptic disorders in phase 2 clinical trials
Relutrigine reduced seizures by 46% and achieved seizure freedom in 30% of pediatric patients with SCN2A and SCN8A DEE, also improving alertness, behavior, and communication.
Novo Nordisk starts new Phase III study with Wegovy successor - MedWatch
Novo Nordisk launched a Phase III trial for cagrisema, intended as the successor to its best-selling weight loss drug Wegovy.
Plus Therapeutics Showcases New Interim ReSPECT-GBM Phase 2 Trial Data at the 2024 ...
Plus Therapeutics to present data on its Rhenium-186 Nanoliposome therapy for recurrent glioblastoma at the 2024 Congress of Neurological Surgeons Annual Meeting, highlighting progress in its ReSPECT-GBM Phase 2 trial.
BriaCell Announces FDA-Authorized Expanded Access Policy for Metastatic Breast Cancer Patients
BriaCell Therapeutics Corp. announces FDA authorization of an Expanded Access Policy (EAP) for metastatic breast cancer patients, allowing access to Bria-IMT™ regimen beyond the Phase 3 trial, under the condition of Fast Track designation.
New Data to be Presented from EFTISARC-NEO Phase II - GlobeNewswire
EFTISARC-NEO trial results of efti, radiotherapy, and KEYTRUDA® to be presented at CTOS 2024. First trial to evaluate efti in neoadjuvant setting for soft tissue sarcoma, showing promising initial efficacy. STS has high unmet medical need and poor prognosis.
Accord BioPharma, Inc. Announces U.S. Food & Drug Administration Approval of 420mg ...
FDA approves 420mg strength of HERCESSI™, a biosimilar to Herceptin®, enabling Accord BioPharma to launch its first biosimilar in the U.S. in early 2025. HERCESSI is indicated for HER2-overexpressing breast and gastric cancers, with data showing similarity to Herceptin in efficacy, safety, and quality.
Biosyngen's first-in-class CAR-T asset targeting solid tumors has entered pivotal phase II ...
Biosyngen presents Phase I data for its CAR-T therapy BRG01 targeting EBV antigens in NPC at the 2024 ESMO Annual Congress, highlighting safety and efficacy, with 75% of patients showing tumor reduction and extended progression-free survival.
MIRA Pharmaceuticals Advances Ketamir-2 Development Following Phase 1 Design ...
MIRA Pharmaceuticals announces progress in developing its novel oral ketamine analog, Ketamir-2, targeting neuropathic pain and other neurologic conditions. The company plans to file an IND with the FDA in December 2024 and aims to demonstrate clinical efficacy as early as 2025 through innovative Phase I/II study designs. MIRA is also exploring additional indications in mental health, including MDD-SI, TRD, and PTSD.
